11C-MCG: Synthesis, Uptake Selectivity, and Primate PET of a Probe for Glutamate Carboxypeptidase II (NAALADase)

被引:110
作者
Pomper, Martin G. [1 ]
Musachio, John L. [1 ]
Zhang, Jiazhong [2 ]
Scheffel, Ursula [1 ]
Zhou, Yun [1 ]
Hilton, John [1 ]
Maini, Atul [1 ]
Dannals, Robert F. [1 ]
Wong, Dean F. [1 ]
Kozikowski, Alan P. [2 ]
机构
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD 21287 USA
[2] Georgetown Univ, Med Ctr, Washington, DC 20057 USA
关键词
Glutamate carboxypeptidase; NAALADase; urea-based inhibitor; C-11-MCG; PET;
D O I
10.1162/153535002320162750
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Imaging of glutamate carboxypeptidase II (GCP II), also known as N-acetylated a-linked L-amino dipeptidase (NAALADase), may enable study of glutamatergic transmission, prostate cancer, and tumor neovasculature in vivo. Our goal was to develop a probe for GCP II for use with positron emission tomography (PET). Radiosynthesis of C-11-MeCys-C(O)-Glu or C-11-(S)-2-[3-((R)-1-carboxy-2-methylsulfanyl-ethyl)-ureido]pentanedioic acid (C-11-MCG), an asymmetric urea and potent (K-i = 1.9 nM) inhibitor of GCP II, was performed by C-11 methylation of the free thiol. Biodistribution of C-11-MCG was assayed in mice, and quantitative PET was performed in a baboon. C-11-MCG was obtained in 16% radiochemical yield at the end of synthesis with specific radioactivities over 167 GBq/mmol (4000 Ci/mmol) within 30 min after the end of bombardment. At 30 min postinjection, C-11-MCG showed 33.0 +/- 5.1%, 0.4 +/- 0.1%, and 1.1 +/- 0.2% ID/g in mouse kidney (target tissue), muscle, and blood, respectively. Little radioactivity gained access to the brain. Blockade with unlabeled MCG or 2-(phosphonomethyl)pentanedioic acid (PMPA), another potent inhibitor of GCP II, provided sevenfold and threefold reductions, respectively, in binding to target tissue. For PET, distribution volumes (DVs) were 1.38 then 0.87 pre- and postblocker (PMPA). Little metabolism of C-11-MCG occurred in the mouse or baboon. These results suggest that C-11-MCG may be useful for imaging GCP II in the periphery.
引用
收藏
页码:96 / 101
页数:6
相关论文
共 18 条
[1]   Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase [J].
Carter, RE ;
Feldman, AR ;
Coyle, JT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (02) :749-753
[2]  
Chang SS, 1999, CANCER RES, V59, P3192
[3]   Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers [J].
Gong, MC ;
Chang, SS ;
Sadelain, M ;
Bander, NH ;
Heston, WDW .
CANCER AND METASTASIS REVIEWS, 1999, 18 (04) :483-490
[4]   Introduction: Glutamate transport, metabolism, and physiological responses [J].
Hediger, MA ;
Welbourne, TC .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 1999, 277 (04) :F477-F479
[5]  
HOROSZEWICZ JS, 1987, ANTICANCER RES, V7, P927
[6]   Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase [J].
Jackson, PF ;
Cole, DC ;
Slusher, BS ;
Stetz, SL ;
Ross, LE ;
Donzanti, BA ;
Trainor, DA .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (02) :619-622
[7]   Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase) [J].
Kozikowski, AP ;
Nan, F ;
Conti, P ;
Zhang, JH ;
Ramadan, E ;
Bzdega, T ;
Wroblewska, B ;
Neale, JH ;
Pshenichkin, S ;
Wroblewski, JT .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (03) :298-301
[8]  
Lapidus RG, 2000, PROSTATE, V45, P350, DOI 10.1002/1097-0045(20001201)45:4<350::AID-PROS10>3.0.CO
[9]  
2-U
[10]  
LOPES AD, 1990, CANCER RES, V50, P6423